Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
Climb Bio and partner Mabworks presented Phase 1 data for CLYM116/MIL116, an anti-APRIL antibody for IgA nephropathy, at ASN Kidney Week 2026, showing ≥90% free APRIL suppression sustained through 12 weeks after a single subcutaneous dose. A single 800 mg dose produced ~70% reduction in Gd-IgA1 and ~60% reduction in IgA at 12 weeks, with a ~33-day half-life supporting an every-12-week dosing regimen and a clean safety profile.
Key figures
- Drug Name
- CLYM116/MIL116
- Phase Of Trial
- Phase 1
- Dose range
- 25 mg to 1280 mg
- Iga reduction
- ~60% at 12 weeks (800 mg dose)
- Half life days
- ~33 days (3.5x sibeprenlimab)
- Gd iga1 reduction
- ~70% at 12 weeks (800 mg dose)
- Phase1 enrollment
- 46 participants (Australia) and 42 (China)
- Aprill suppression
- ≥90% free APRIL suppression sustained through 12 weeks (single SC dose ≥480 mg)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.